Atos multiplies supercomputing capacity by 12 at CESGA in Spain with new “Finisterrae III”
Santiago de Compostela (Galicia, Spain), Paris (France) July 29, 2021 Atos has been selected by
III
Destiny Pharma PLC making significant strides towards phase III evaluation of potential breakthrough C.diff treatment
CEO Neil Clark claimed: “We have built substantial development since closing the £10.4mln fairness funding
AstraZeneca vaccine shows 79{d5f2c26e8a2617525656064194f8a7abd2a56a02c0e102ae4b29477986671105} efficacy in phase III trial
(Picture by Halfpoint Visuals/Getty Visuals) AstraZeneca’s COVID-19 vaccine has just gone through a period III